Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 3 study of Iberogast (STW 5) in irritable bowel syndrome
2011-002613-10Phase 3Completed
- Sponsor
- Steigerwald Arzneimittelwerk
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Iberogast (STW 5) with Placebo (2 arms). Primary endpoint: Pain Intensity Responder at 4 Weeks. Started Oct 2011; status: completed.
02
Drugs
Iberogast
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2011-002613-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002613-10.